
Drug Fails to Make a Difference in Nonalcoholic Steatohepatitis
According to a story from Proactive Investors, the biotechnology company Conatus Pharmaceuticals recently reported that the company's drug Emricasan failed to achieve the primary endpoint in a Phase 2b clinical…